Revenio Group OyjCHIX:REG1VH 77 Days Payable is 128.36 as of Mar. 2026, which is 51% above its 10-year median of 85.26. GuruFocus rates CHIX:REG1VH with a GF Score™ of 77/100 and a GF Value™ of €40.60. The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 74.09% on this metric.
The historical rank and industry rank for Revenio Group Oyj's Days Payable or its related term are showing as below:
CHIX:REG1Vh'
s Days Payable Range Over the Past 10 Years
Min: 27.27 Med: 85.26 Max: 129.82
Current: 129.82
During the past 13 years, Revenio Group Oyj's highest Days Payable was 129.82. The lowest was 27.27. And the median was 85.26.
CHIX:REG1Vh's Days Payable is ranked better than 74.09% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs CHIX:REG1Vh: 129.82
Revenio Group Oyj's Days Payable
increased
from Mar. 2025 (115.05) to Mar. 2026 (128.36).
It may suggest that Revenio Group Oyjdelayed paying its suppliers.
Revenio Group Oyj Days Payable Related Terms
Revenio Group Oyj Days Payable Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:REG1VH vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Revenio Group Oyj's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Days Payable distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Revenio Group Oyj's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revenio Group Oyj (CHIX:REG1VH) has a Days Payable of 128.36 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Revenio Group Oyj and its competitors. This is 51% above median its historical median of 85.26. Over the past decade, Revenio Group Oyj's Days Payable has ranged from 27.27 to 129.82. According to the industry distribution chart, Revenio Group Oyj ranks #206 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 25.9%.
Is Revenio Group Oyj's Days Payable too high?
Revenio Group Oyj's current Days Payable of 128.36 is 51% above median its 10-year median of 85.26. Over the past 10 years, this metric has ranged from a low of 27.27 to a high of 129.82. The Medical Devices & Instruments industry median Days Payable is 68.07. Revenio Group Oyj's value of 128.36 is 88.6% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #206 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Revenio Group Oyj has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #206 out of 795 companies for Days Payable. This puts Revenio Group Oyj in the upper half of its industry. The industry median Days Payable is 68.07. Revenio Group Oyj's value of 128.36 is 88.6% above this benchmark. Historically, Revenio Group Oyj's own Days Payable has ranged from 27.27 to 129.82 over the past decade. While the company's 10-year median is 85.26 vs. the industry median of 68.07, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current Days Payable of 128.36 is 88.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current Days Payable is 128.36, which is 51% above median its own 10-year median of 85.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Revenio Group Oyj (CHIX:REG1VH) has a current Days Payable of 128.36. The stock's GF Value™ is €40.60, compared to a current price of €16.47 — trading 59.4% below its estimated fair value. The current Days Payable is 128.36, which is 51% above median its 10-year median of 85.26 and 88.6% above the Medical Devices & Instruments industry median of 68.07. Revenio Group Oyj's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Revenio Group Oyj (CHIX:REG1VH), the current Days Payable is 128.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (CHIX:REG1VH) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of €16.47 is trading 59.4% below its estimated GF Value™ of €40.60.
Key valuation signals for CHIX:REG1VH:
Days Payable: 128.36 (51% above median its 10-year median of 85.26)
GF Value™: €40.60 vs. price of €16.47 (59.4% below fair value)
Industry Position: 88.6% above the Medical Devices & Instruments median (#206 of 795)
No single metric tells the full story. See the CHIX:REG1VH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
77GF Score
Get the complete analysis for CHIX:REG1VH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:REG1VH has been successfully added to your 
